Accomplishments are evidenced by approved products and an advancing pipeline. Seven marketed and partnered products validate our technology and development approach.
A Leader in Inhaled Pharmaceuticals
Our collaborative approach to drug development is seen both internally and in successful partnerships. Partners include Novartis, Sandoz, Baxter and GSK.
Our formulation technologies and proprietary devices enable delivery directly to the lungs and underpin the company’s development pipeline.
Know-how and experience fuels innovation. Our experienced teams of scientists focus on developing innovative solutions in all areas of drug development.
Our drug development efforts are focused on bronchopulmonary disease - a high unmet need and growing multi billion market.
Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.
21 May 2013
New data presented at the American Thoracic Society meeting highlights strength of once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
Vectura Group plc – Preliminary Results for the year ended 31 March 2013
Our innovative and broad clinical pipeline combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors
View our product pipeline
Vectura establishes strategic partnership (Kinnovata) for new respiratory business in China.
Chippenham, UK – 13 May 2013:Vectura Group plc (LSE: VEC) ("Vectura"), announces that it has established Tianjin Kinnovata Pharmaceutical Company Limited ("Kinnovata") in China with two partners; Tianjin KingYork Group Company Limited ("KingYork"), a leading Chinese pharmaceutical company and specialist manufacturer of corticosteroid based products, and Zendex Bio Strategy Inc ("Zendex"), a private equity investor based in Hong Kong.
Share price details
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.